360Dx

Sequenom Q2 Revenues Fall 11 Percent on Lower Reimbursement Rates for NIPT

Aug 08, 2016

This article has been updated to clarify the reasons for the year-over-year decline in diagnostic services revenue.

NEW YORK (GenomeWeb) – Sequenom's second quarter 2016 revenues fell 11 percent compared to the second quarter of 2015, the firm reported in a filing with the US Securities Exchange Commission.

The molecular diagnostics company reported $29.3 million in Q2 2016 revenues, down from $32.8 million in Q2 2015, missing analysts' average estimate of $30.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Sequenom Q2 Revenues Fall 11 Percent on Lower Reimbursement Rates for NIPT

To read the full story....

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Praxis Genomics Bets on Bionano Optical Maps, Sequencing to Solve Complex Rare Disease Cases

Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

Scipher Medicine Taps Ambry Genetics to Scale Up TNF Inhibitor Response Test

Sponsorships